TICKERNERD
Menu
TRAXHealthcare · Biotechnology

TRAX Stock Forecast: First Tracks Biotherapeutics, Inc. Price Predictions for 2026-2027

Last close, 22 Oct 2026
$43
+0.87% on the day

The 12 Wall Street analysts covering First Tracks Biotherapeutics, Inc. hold a median 12-month price target of $70 — +62.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 1 of 100 as at 21 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$1.5B
Ticker Nerd rank
1/ 100
Median analyst target
$70
Analysts covering
12
Revenue$0.0
Operating income−$34.9M
Net income−$33.4M
Free cash flow−$31.9M
Quarterly, 4 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+19.7%
1M
+5.1%
From high
−10.0%
From low
+181.6%
$15
$48
Range since 15 Apr 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

TRAX stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores First Tracks Biotherapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Oct 2026
1/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
39
Revisions
28
Momentum
21
Value
16
Issuance
8
Accruals
8
Growth
8
Quality
5
Volatility
3

Size (39): Smaller than most of the companies we track.

Volatility (3): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TRAX stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TRAX, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 15 Apr 2026Adjusted close, US dollars
$20$40$60$80$100May 26Jun 26Jul 26Aug 26Sep 26Oct 26TRAXHigh $100Median $70Low $57

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $57Median $70High $100

The green dot is the last close — the median target sits +62.3% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 8 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
16 Oct 2026Leerink PartnersMaintainsOutperform$70 → $90
13 Oct 2026Canaccord GenuityMaintainsBuy$50 → $60
13 Oct 2026Evercore ISI GroupMaintainsOutperform$65 → $70
13 Oct 2026Wells FargoMaintainsOverweight$62 → $70
30 Sept 2026Canaccord GenuityInitiatesBuy—
30 Sept 2026Canaccord GenuityInitiatesBuy$50
18 Sept 2026Evercore ISI GroupInitiatesOutperform—
18 Sept 2026Evercore ISI GroupInitiatesOutperform$65
16 Sept 2026GuggenheimInitiatesBuy$100
16 Sept 2026GuggenheimInitiatesBuy—
3 Sept 2026HC Wainwright & Co.ReiteratesBuy$57
3 Sept 2026HC Wainwright & Co.ReiteratesBuy—
13 Aug 2026BarclaysMaintainsOverweight$48 → $65
13 Aug 2026BarclaysMaintainsOverweight—
13 Aug 2026HC Wainwright & Co.MaintainsBuy—
13 Aug 2026HC Wainwright & Co.MaintainsBuy$44 → $57
13 Aug 2026Piper SandlerMaintainsOverweight—
13 Aug 2026Piper SandlerMaintainsOverweight$54 → $95
13 Aug 2026WedbushMaintainsOutperform$60 → $70
13 Aug 2026WedbushMaintainsOutperform—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

TRAX appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.
  • The AI build-out, every Wednesday: how AI stocks did, part by part.

Free. Unsubscribe any time.

Performance

TRAX vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

TRAX vs S&P 500, last 12 monthsTotal return, rebased to 100
50100150200May 26Jun 26Jul 26Aug 26Sep 26Oct 26TRAXS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

TRAX analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
5
Fundamentals

First Tracks Biotherapeutics, Inc. (TRAX) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
9.0×

Cheaper than 12% of US stocks

EV / EBITDA
−8.1×

Cheaper than 83% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−41.8%

Higher than 24% of US stocks

Return on assets
−37.0%

Higher than 11% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

First Tracks Biotherapeutics, Inc. (TRAX) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • First Tracks Biotherapeutics, Inc. has a market value of $1.5B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$173.5M.

  • Diluted earnings per share, trailing twelve months: $−4.98.

  • Free cash flow in the twelve months to 30 June 2026: −$148.2M.

  • Shares outstanding: 35.4M.

  • forward P/E: −11.8× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • First Tracks Biotherapeutics, Inc. employs 104 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Oct 2026

Data provided by Twelve Data

Peers

TRAX vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
TRAXFirst Tracks Biotherapeutics, Inc.$1.5B1
KRSAKorsana Biosciences, Inc.$1.5B44
INBXInhibrx Biosciences, Inc.$1.4B24
ORICOric Pharmaceuticals, Inc.$1.4B49
QUREuniQure NV$1.5B47
OCULOcular Therapeutix, Inc.$1.4B35
ANABAnaptysBio, Inc.$1.4B95

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own First Tracks Biotherapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TRAX news & analysis

First Tracks Biotherapeutics Announces $200 Million Private Placement

GlobeNewsWire · 15 Oct 2026positive

First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 common shares to institutional investors in a private placement at $32.75 per share. The company anticipates approximately $200 million in gross proceeds before fees and other expenses.

Why it matters — The private placement would provide TRAX with approximately $200 million in gross proceeds before expenses.

First Tracks Biotherapeutics: Teva Validated The Pathway, ANB033 May Own The Receptor

Seeking Alpha · 14 Oct 2026positive

Seeking Alpha reports that First Tracks Biotherapeutics’ ANB033 showed statistically significant histology and symptom improvements in Phase 1b celiac disease data, with a stronger efficacy signal than Teva’s IL-15 inhibitor in the reported comparison. The excerpt cites $168 million in cash, a projected runway into Q2 2028, plans for late-stage celiac trials and two additional indications, and a likely need for further financing.

Why it matters — The reported clinical data and cash runway may be relevant to TRAX watchers assessing its celiac program, planned expansion, and financing needs.

First Tracks' ANB033 Clears Key Phase Ib Celiac Disease Study Goals

MarketBeat · 12 Oct 2026positive

First Tracks Biotherapeutics reported top-line results from the first cohort of its Phase Ib ANB033 study in celiac disease. The company said the CD122 antagonist met histologic and symptom-related objectives during a placebo-controlled gluten challenge.

Why it matters — The results provide an update on a clinical-stage program relevant to TRAX watchers.

First Tracks Biotherapeutics Announces Participation in September Investor Conferences

GlobeNewsWire · 26 Aug 2026neutral

First Tracks Biotherapeutics, a clinical-stage biotechnology company advancing antibody therapeutics for autoimmune and inflammatory diseases, announced that members of its executive team are scheduled to participate in multiple investor conferences in September. This was disclosed in an Aug. 26, 2026 press release from San Diego.

Why it matters — The company's executive team's participation in upcoming investor conferences provides an opportunity for increased visibility and engagement with the investment community.

FAQ

Frequently asked questions about TRAX stock

What is the TRAX stock price forecast for 2026-2027?

The 12 Wall Street analysts covering First Tracks Biotherapeutics, Inc. have a median 12-month price target of $70, with estimates ranging from $57 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TRAX stock a buy right now?

Of the 12 analysts covering First Tracks Biotherapeutics, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks First Tracks Biotherapeutics, Inc. 1 out of 100 across roughly 4,600 US stocks as at 21 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TRAX?

As at 21 Oct 2026, First Tracks Biotherapeutics, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (39 of 100).

Will TRAX stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +62.3% from the last close, and Ticker Nerd's factor model ranks First Tracks Biotherapeutics, Inc. 1 out of 100 as at 21 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TRAX stock forecast for 2030?

No analyst covering First Tracks Biotherapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TRAX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $57 to $100 over the next 12 months.

What does First Tracks Biotherapeutics, Inc. do?

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases.

What is the latest news on TRAX?

The most recent item we track (GlobeNewsWire, 15 Oct 2026): "First Tracks Biotherapeutics Announces $200 Million Private Placement". First Tracks Biotherapeutics entered into a securities purchase agreement to sell 6,106,870 common shares to institutional investors in a private placement at $32.75 per share. The company anticipates approximately $200 million in gross proceeds before fees and other expenses.

Company

About First Tracks Biotherapeutics, Inc.

First Tracks Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. The company’s current pipeline centers on three antibody-based programs: rosnilimab, designed to selectively deplete pathogenic T cells; ANB033, an anti-CD122 antagonist being studied in immune-mediated conditions such as celiac disease and eosinophilic esophagitis; and ANB101, a BDCA2-modulating antibody targeting plasmacytoid dendritic cells. Its work is concentrated in research and development, with a focus on advancing therapies that address immune pathway dysfunction across rheumatology and gastroenterology settings. First Tracks Biotherapeutics, Inc. operates as a specialized player in the biotechnology market, contributing to the broader development of targeted treatments for complex inflammatory disorders.

CEO Mr. Daniel R. Faga · 104 employees · United States · https://www.firsttracksbio.com